Claims for Patent: 12,097,202

Summary for Patent: 12,097,202

Title:	Methods of administering Belumosudil for treatment of chronic graft versus host disease
Abstract:	The present disclosure provides methods of administering belumosudil mesylate salt to patients with chronic graft-versus-host disease (cGVHD), wherein the methods include identifying adverse reactions in the patients, such as an infection, and modifying the administration based on the results of such identification, such as by ceasing administration when the infection is a Grade 3 or Grade 4 level infection.
Inventor(s):	David Eiznhamer, Heidi Krenz
Assignee:	Kadmon Corp LLC
Application Number:	US18/105,285
Patent Claims:	1. A method of treating chronic graft-versus-host disease (cGVHD) in a patient in need thereof comprising the steps of: (a) administering 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy }-N-(propan-2-yl) acetamide, or a pharmaceutically acceptable salt thereof (Compound) to the patient at a daily dose that is equivalent to 200 mg of the free base of the Compound; (b) identifying an adverse reaction in the patient, wherein the adverse reaction is an infection; (c) ceasing administration of the Compound to the patient when the adverse reaction is an infection at a Grade 3 level; wherein an infection at a Grade 3 level comprises an infection wherein intravenous (IV) antibiotic, antifungal, antiviral, radiological or operative intervention is indicated; and (d) resuming administration of the Compound to the patient at the previously administered daily dose when the patient's infection has recovered to Grade 1 level or less, wherein an infection at a Grade 1 level comprises an infection wherein intervention is not indicated. 2. A method of treating chronic graft-versus-host disease (cGVHD) in a patient in need thereof comprising the steps of: (a) administering 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide, or a pharmaceutically acceptable salt thereof (Compound) to the patient at a daily dose that is equivalent to 200 mg of the free base of the Compound; (b) identifying an adverse reaction in the patient, wherein the adverse reaction is an infection; (c) permanently ceasing administration of the Compound to the patient when the patient's adverse reaction comprises a Grade 4 level infection, wherein a Grade 4 level infection comprises an infection that is life-threatening and wherein urgent intervention is indicated. 3. The method according to claim 1, wherein the Compound is belumosudil mesylate salt. 4. The method according to claim 1, wherein the patient has failed at least two prior lines of systemic therapy for the cGVHD. 5. The method according to claim 2, wherein the Compound is belumosudil mesylate salt. 6. The method according to claim 2, wherein the patient has failed at least two prior lines of systemic therapy for the cGVHD.